WOOLSEY PHARMACEUTICALS
Woolsey Pharmaceuticals is a pharmaceutical company that specializes in reinventing ways to treat some of the world’s most challenging diseases. The company's approach allows them to accelerate the delivery of medicines for the benefit of all humankind. The company was founded in 2019 and is headquartered in New York, United States.
WOOLSEY PHARMACEUTICALS
Industry:
Biotechnology Health Care Health Diagnostics Medical Pharmaceutical
Founded:
2019-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.woolseypharma.com
Total Employee:
1+
Status:
Active
Contact:
212-586-2226
Total Funding:
28.26 M USD
Technology used in webpage:
Domain Not Resolving Google Apps For Business Twitter Tweet Button Facebook Like Button Facebook Like
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Current Advisors List
Board_member
2020-01-01
Current Employees Featured
Sven M. Jacobson Co-Founding Partner & Chief Executive Officer @ Woolsey Pharmaceuticals
Co-Founding Partner & Chief Executive Officer
2019-11-01
David M. Geliebter Co-Founder & Executive Chairman @ Woolsey Pharmaceuticals
Co-Founder & Executive Chairman
2019-12-01
Founder
Investors List
Shane Neman
Shane Neman investment in Series B - Woolsey Pharmaceuticals
Nelstone Ventures
Nelstone Ventures investment in Venture Round - Woolsey Pharmaceuticals
Official Site Inspections
http://www.woolseypharma.com
- Host name: 237.112.212.35.bc.googleusercontent.com
- IP address: 35.212.112.237
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Woolsey Pharmaceuticals"
About Us | Woolsey Pharmaceuticals, Inc.
We recognize the courage and strength it takes to face these deadly, debilitating neurodegenerative disorders — a recognition that fuels our determination to ease suffering …See details»
Woolsey Pharmaceuticals, Inc.
Woolsey pharmaceuticals is expanding the boundaries of medical science. Our mission is to help usher in a new era of neurodegenerative disease treatment.See details»
The Team - Woolsey Pharmaceuticals, Inc.
/*! elementor - v3.19.0 - 07-02-2024 */ .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-headingSee details»
Woolsey Pharmaceuticals - Crunchbase Company Profile & Funding
Woolsey Pharmaceuticals is a pharmaceutical company that specializes in reinventing ways to treat some of the world’s most challenging diseases.See details»
Woolsey Pharmaceuticals Profile and History - Datanyze
Www.woolseypharma.com Woolsey Pharmaceuticals Profile and History New York-based Woolsey Pharmaceuticals is a single-drug entity focused on the treatment of rare, …See details»
Woolsey Pharmaceuticals - The Org
Woolsey Pharmaceuticals is a pharmaceutical company that specializes in reinventing ways to treat some of the world’s most challenging diseases. The company's approach allows them to …See details»
Woolsey Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Woolsey Pharmaceuticals, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Woolsey Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
Www.woolseypharma.com. Last update 01 Mar 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. ... The statistics for …See details»
Woolsey Pharmaceuticals | VentureRadar
Website: https://www.woolseypharma.com/ Focuses on treating rare, neurodegenerative diseases by identifying new uses for existing drugs where no therapeutic solutions ...See details»
Woolsey Pharmaceuticals - LinkedIn
Sabrina Williams Director, Clinical and Regulatory Affairs at Woolsey Pharmaceuticals david geliebter Co-Founder at Embark HealthcareSee details»
Woolsey Pharmaceuticals - PitchBook
Www.woolseypharma.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 233 Broadway; Suite 1750; New York, NY 10279; United …See details»
Woolsey Pharmaceuticals Completes B Round Extension To …
NEW YORK – February 27, 2025, Woolsey Pharmaceuticals today announced the successful completion of an extension to its Series B Preferred financing round by existing investors.See details»
Woolsey Pharmaceuticals Inc Overview - Salary.com
Discover essential details about Woolsey Pharmaceuticals Inc, including address, contact, and journey of our company's evolution.See details»
Contact | Woolsey Pharmaceuticals, Inc.
The Woolworth Building is frequently hailed as the “cathedral of commerce.” This Gothic marvel exudes a timeless charm that harmonizes with the rich history of countless legendary companies.See details»
Woolsey Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
Explore Woolsey Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 2 news, Disease Domain:Nervous System Diseases ...See details»
Woolsey Pharmaceuticals - VentureRadar
Website: https://www.woolseypharma.com/ Woolsey Pharmaceuticals is focused on the treatment of rare, neurodegenerative diseases. Woolsey Pharmaceuticals does not ...See details»
Woolsey Pharmaceuticals, Inc. (Woolsey Pharmaceuticals, Inc.) - 药 …
NEW YORK, Dec. 9, 2024 /PRNewswire/ -- Woolsey Pharmaceuticals, a clinical-stage pharmaceutical company developing BRAVYL (oral fasudil) for the treatment of Amyotrophic …See details»
Woolsey Pharmaceuticals - Products, Competitors, Financials, …
Headquarters Location. 233 Broadway Suite 1750. New York, New York, 10279, United States. 212-586-2226See details»
Overview, News & Similar companies - ZoomInfo.com
Feb 17, 2021 View Woolsey Pharmaceuticals (www.woolseypharma.com) location in New York, United States , revenue, industry and description. Find related and similar companies as well …See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»